Outcome of defined karyotype groups
. | . | Outcome of induction therapy . | . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|
. | No.(%) . | CR, no.(%) . | Resistant disease, no.(%) . | Induction death, no.(%) . | Relapsed, no.(%) . | 5-y DFS, % (95% CI) . | 5-y OS, % (95% CI) . | ||
| Normal | 287 (45) | 163 (57) | 75 (26) | 49 (17) | 135 (83) | 9 (5-14) | 8 (5-12) | ||
| −7/7q− | 97 (15) | 37 (38) | 44 (45) | 16 (16) | 30 (81) | 3 (0.2-12) | 2 (0.4-7) | ||
| +8 | 88 (14) | 35 (40) | 31 (35) | 22 (25) | 29 (83) | 9 (2-21) | 7 (3-13) | ||
| −5/5q− | 86 (14) | 19 (22) | 44 (51) | 23 (27) | 18 (95) | 0 | 0 | ||
| −17/17p− | 58 (9) | 16 (28) | 25 (43) | 17 (29) | 16 (100) | 6 (0.4-25) | 2 (0.1-8) | ||
| −12/12p− | 38 (6) | 7 (18) | 23 (61) | 8 (21) | 7 (100) | 0 | 0 | ||
| CBF AML | 31 (5) | 24 (77) | 3 (10) | 4 (13) | 18 (75) | 17 (5-34) | 19 (8-35) | ||
| t(8;21) | 15 (2) | 11 (73) | 2 (13) | 2 (13) | 7 (64) | 27 (7-54) | 20 (5-42) | ||
| inv(16) | 16 (3) | 13 (81) | 1 (6) | 2 (13) | 11 (85) | 8 (0.5-29) | 19 (5-40) | ||
| −18 | 29 (5) | 6 (21) | 13 (45) | 10 (34) | 6 (100) | 0 | 0 | ||
| −Y | 28 (4) | 14 (50) | 8 (29) | 6 (21) | 11 (79) | 14 (2-37) | 11 (3-25) | ||
| −11/11q− | 28 (4) | 10 (36) | 14 (50) | 4 (14) | 9 (90) | 10 (0.6-36) | 4 (0.3-15) | ||
| −20/20q− | 28 (4) | 5 (18) | 18 (64) | 5 (18) | 4 (80) | 0 | 0 | ||
| +11 | 24 (4) | 10 (42) | 9 (38) | 5 (21) | 10 (100) | 0 | 0 | ||
| +13 | 20 (3) | 12 (60) | 2 (10) | 6 (30) | 9 (75) | 8 (0.5-31) | 5 (0.3-21) | ||
| +21 | 20 (3) | 8 (40) | 8 (40) | 4 (20) | 7 (88) | 0 | 0 | ||
| −9/9q− | 17 (3) | 10 (59) | 2 (12) | 5 (29) | 9 (90) | 10 (0.6-36) | 6 (0.4-24) | ||
| −13/13q− | 17 (3) | 5 (29) | 9 (53) | 3 (18) | 4 (80) | 20 (0.8-58) | 6 (0.4-24) | ||
| Balanced abnormalities involving band 11 q23 | 17 (3) | 10 (59) | 4 (24) | 3 (18) | 7 (70) | 10 (0.6-36) | 12 (2-31) | ||
| +22 | 17 (3) | 7 (41) | 6 (35) | 4 (24) | 6 (86) | 14 (0.7-46) | 6 (0.4-24) | ||
| Rare aberrations | 33 (5) | 10 (30) | 12 (36) | 11 (33) | 10 (100) | 0 | 0 | ||
| Complex karyotype, at least 3 abnormalities in a single clone | 122 (19) | 30 (25) | 61 (50) | 31 (25) | 27 (90) | 3 (0.2-15) | 2 (0.3-5) | ||
| Complex karyotype, at least 5 abnormalities in a single clone | 94 (15) | 22 (23) | 46 (49) | 26 (28) | 21 (95) | 0 | 0 | ||
. | . | Outcome of induction therapy . | . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|
. | No.(%) . | CR, no.(%) . | Resistant disease, no.(%) . | Induction death, no.(%) . | Relapsed, no.(%) . | 5-y DFS, % (95% CI) . | 5-y OS, % (95% CI) . | ||
| Normal | 287 (45) | 163 (57) | 75 (26) | 49 (17) | 135 (83) | 9 (5-14) | 8 (5-12) | ||
| −7/7q− | 97 (15) | 37 (38) | 44 (45) | 16 (16) | 30 (81) | 3 (0.2-12) | 2 (0.4-7) | ||
| +8 | 88 (14) | 35 (40) | 31 (35) | 22 (25) | 29 (83) | 9 (2-21) | 7 (3-13) | ||
| −5/5q− | 86 (14) | 19 (22) | 44 (51) | 23 (27) | 18 (95) | 0 | 0 | ||
| −17/17p− | 58 (9) | 16 (28) | 25 (43) | 17 (29) | 16 (100) | 6 (0.4-25) | 2 (0.1-8) | ||
| −12/12p− | 38 (6) | 7 (18) | 23 (61) | 8 (21) | 7 (100) | 0 | 0 | ||
| CBF AML | 31 (5) | 24 (77) | 3 (10) | 4 (13) | 18 (75) | 17 (5-34) | 19 (8-35) | ||
| t(8;21) | 15 (2) | 11 (73) | 2 (13) | 2 (13) | 7 (64) | 27 (7-54) | 20 (5-42) | ||
| inv(16) | 16 (3) | 13 (81) | 1 (6) | 2 (13) | 11 (85) | 8 (0.5-29) | 19 (5-40) | ||
| −18 | 29 (5) | 6 (21) | 13 (45) | 10 (34) | 6 (100) | 0 | 0 | ||
| −Y | 28 (4) | 14 (50) | 8 (29) | 6 (21) | 11 (79) | 14 (2-37) | 11 (3-25) | ||
| −11/11q− | 28 (4) | 10 (36) | 14 (50) | 4 (14) | 9 (90) | 10 (0.6-36) | 4 (0.3-15) | ||
| −20/20q− | 28 (4) | 5 (18) | 18 (64) | 5 (18) | 4 (80) | 0 | 0 | ||
| +11 | 24 (4) | 10 (42) | 9 (38) | 5 (21) | 10 (100) | 0 | 0 | ||
| +13 | 20 (3) | 12 (60) | 2 (10) | 6 (30) | 9 (75) | 8 (0.5-31) | 5 (0.3-21) | ||
| +21 | 20 (3) | 8 (40) | 8 (40) | 4 (20) | 7 (88) | 0 | 0 | ||
| −9/9q− | 17 (3) | 10 (59) | 2 (12) | 5 (29) | 9 (90) | 10 (0.6-36) | 6 (0.4-24) | ||
| −13/13q− | 17 (3) | 5 (29) | 9 (53) | 3 (18) | 4 (80) | 20 (0.8-58) | 6 (0.4-24) | ||
| Balanced abnormalities involving band 11 q23 | 17 (3) | 10 (59) | 4 (24) | 3 (18) | 7 (70) | 10 (0.6-36) | 12 (2-31) | ||
| +22 | 17 (3) | 7 (41) | 6 (35) | 4 (24) | 6 (86) | 14 (0.7-46) | 6 (0.4-24) | ||
| Rare aberrations | 33 (5) | 10 (30) | 12 (36) | 11 (33) | 10 (100) | 0 | 0 | ||
| Complex karyotype, at least 3 abnormalities in a single clone | 122 (19) | 30 (25) | 61 (50) | 31 (25) | 27 (90) | 3 (0.2-15) | 2 (0.3-5) | ||
| Complex karyotype, at least 5 abnormalities in a single clone | 94 (15) | 22 (23) | 46 (49) | 26 (28) | 21 (95) | 0 | 0 | ||